NKGen Biotech, Inc.
NKGN
$0.06
$0.000.00%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -3.46% | 15.87% | 66.23% | 74.32% | 68.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.45% | -9.34% | 17.79% | 22.40% | 21.61% |
| Operating Income | 21.45% | 9.34% | -17.79% | -22.42% | -21.80% |
| Income Before Tax | 70.63% | 46.67% | 13.89% | -196.08% | -180.60% |
| Income Tax Expenses | 657.14% | 657.14% | 0.00% | 0.00% | 0.00% |
| Earnings from Continuing Operations | 70.56% | 46.61% | 13.89% | -196.03% | -180.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 70.56% | 46.61% | 13.89% | -196.03% | -180.56% |
| EBIT | 21.45% | 9.34% | -17.79% | -22.42% | -21.80% |
| EBITDA | 22.43% | 9.66% | -18.72% | -23.59% | -22.97% |
| EPS Basic | 82.70% | 72.90% | 51.55% | -52.60% | -56.81% |
| Normalized Basic EPS | 58.72% | 48.03% | 50.55% | -34.03% | -16.16% |
| EPS Diluted | 73.49% | 71.38% | 49.85% | -52.74% | -56.96% |
| Normalized Diluted EPS | 56.47% | 50.66% | 52.92% | -34.03% | -16.16% |
| Average Basic Shares Outstanding | 97.99% | 86.72% | 103.76% | 101.67% | 69.95% |
| Average Diluted Shares Outstanding | 195.95% | 106.49% | 129.41% | 101.67% | 69.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |